Symbols

CAPR

Capricor·NASDAQ

--(--)

CAPR fundamentals

CAPR Q4 2025 Earnings

Capricor (CAPR) released its earnings on Mar 12, 2026: revenue was 0 (YoY -100.00%), missed estimates; EPS was -0.62 (YoY -287.50%), missed estimates.

Revenue / YoY

-100.00%

EPS / YoY

-0.62

-287.50%

Report date

Mar 12, 2026

CAPR Earnings Call Summary for Q4,2025

Regulatory Breakthrough: FDA accepts BLA for Deramiocel with PDUFA date of August 22, 2026, following submission of full HOPE-3 trial data showing 91% disease progression slowing in cardiomyopathy and significant functional improvement in skeletal muscle.
Manufacturing Scale-Up: San Diego facility expands to 2,500 patients/year by late 2027, positioning for global DMD market penetration.
Financial Strength: $318 million cash runway supports operations into 2027, with potential PRV monetization adding $100-200 million.
Pipeline Momentum: StealthX exosome platform advances toward 2027 IND filings, while Deramiocel expansion into Europe and Japan is underway.
Clinical Impact: Deramiocel demonstrates ability to stabilize and improve both cardiac and skeletal muscle function in DMD, with no new safety signals after 800+ infusions.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Capricor (CAPR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Capricor (CAPR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Capricor (CAPR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Capricor (CAPR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown